Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 629

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 629
---
 385

Code of Business Conduct and Ethics New Semnur intends to adopt a written code of business conduct and ethics, effective immediately prior to the closing of the Business Combination, which will apply to New Semnur’s directors, officers and employees, including New Semnur’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon the closing of the Business Combination, a current copy of New Semnur’s code of business conduct and ethics will be posted on its website at www.semnurpharma.com. Information contained on or accessible through such website is not a part of this proxy statement/prospectus, and the inclusion of the website address in this proxy statement/prospectus is an inactive textual reference only. New Semnur intends to disclose any amendments to its code of business conduct and ethics, or any waivers of its requirements, on its website to the extent required by the applicable rules and exchange requirements. Compensation Committee Interlocks and Insider Participation None of the intended members of New Semnur’s compensation committee is currently, or has been at any time in the past year, one of Semnur’s officers or employees. Other than Dr. Ji and Mr. Shah, none of New Semnur’s expected executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of the New Semnur Board or compensation committee. Please see the section of this proxy statement/prospectus titled “ Semnur’s Executive Compensation” for information regarding the compensation of Dr. Ji and Mr. Shah. Limitation of Liability and Indemnification of Directors and Officers The Proposed Charter and the Proposed Bylaws, which will become effective immediately prior to the consummation of the Business Combination, will contain provisions that limit the liability of New Semnur’s directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, New Semnur’s directors will not be personally liable to New Semnur or its stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

| • |     | any breach of their duty of loyalty to New Semnur or its stockholders; |

| • |     | acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; |

| • |     | unlawful payments of dividends or unlawful stock repurchases or